- Details
- Ruchika Talwar interviews Laura Bukavina and Steven Leonard about their study on financial distress for genitourinary cancer patients. Using data from the CDC National Health Interview Survey, they explore how the rising costs of cancer drugs impact patients' financial well-being and access to care. The study reveals that GU cancer patients, particularly those with bladder and kidney cancer, strug...
|
- Details
- Ruchika Talwar interviews Apoorv Dhir and Rishi Sekar about their study on cancer-related financial hardship among cancer survivors. The researchers discuss findings from the HINTS-SEER survey, which reveals that 44% of cancer patients report some level of financial hardship. They highlight the importance of considering both individual and community-level factors in assessing financial burden. The...
|
- Details
- Jason Efstathiou discusses the PARTIQoL trial, a randomized phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou discusses the history and potential benefits of proton therapy, as well as the challenges in conducting comparative studies. He describes the trial design, which focuses on patient-reported outcomes, particularly bowel function at 24 months...
|
- Details
- Ashley Ross and David Morris discuss the use of the Decipher ® Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher ® can help stratify patients and guide treatment decisions, particularly in choosing between monotherapy, doublet, or triplet therapies. The discussion covers the STAMPEDE trial data, showing Decipher's ® ability to predict treatment s...
|
- Details
- Oliver Sartor interviews Bertrand Tombal about the PEACE-3 trial. The study investigates the combination of radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer. Dr. Tombal discusses the trial design, results, and implications. The study demonstrates significant improvements in radiographic progression-free survival an...
|
- Details
- Leslie Ballas interviews Hoda Abdel-Aty about the STAMPEDE2 SABR trial, a Phase III randomized study investigating stereotactic ablative body radiotherapy in newly diagnosed oligometastatic prostate cancer patients starting androgen deprivation therapy. Dr. Abdel-Aty discusses the trial design, which compares standard-of-care treatment with or without SABR to metastases. The study defines oligomet...
|
- Details
- Neeraj Agarwal interviews Arun Azad about the UpFrontPSMA study. Dr. Azad discusses the randomized Phase II trial comparing sequential lutetium-PSMA-617 and docetaxel versus docetaxel alone in metastatic hormone-sensitive prostate cancer (mHSPC). The study demonstrates significant improvements in the primary endpoint of undetectable PSA at 48 weeks and several secondary endpoints with the addition...
|
- Details
- Alicia Morgans interviews David Braun about novel serum glycoproteomic biomarkers in the CheckMate 9ER study for kidney cancer. Dr. Braun discusses the exploratory post-hoc analysis using the InterVenn GlycoVision Glycoproteomics platform to investigate potential prognostic and predictive biomarkers. He highlights findings that higher levels of glycosylation are associated with worse outcomes, reg...
|
- Details
- Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes. Biographies: Jason Hafron, MD, CMO, Oncologist, Director of Research, Michigan I...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about his presentation on T-cell engaging treatments for prostate cancer. Dr. Agarwal discusses the rationale behind T-cell engagers, their potential to bypass the limitations of prostate cancer's cold tumor microenvironment, and the various tumor-associated antigens being targeted. He reviews several bispecific and trispecific T-cell engagers currently in...
|
